PPARG and hepatocellular carcinoma: Celecoxib, a selective COX-2 inhibitor, reduces AKT phosphorylation and induces growth inhibition and apoptosis in HCC cells, stimulating peroxisome proliferator-activated receptor gamma (PPARy) as well as PTEN.